

# Kentaro Igarashi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8271851/publications.pdf>

Version: 2024-02-01

114  
papers

2,688  
citations

159585

30  
h-index

243625

44  
g-index

115  
all docs

115  
docs citations

115  
times ranked

1681  
citing authors

#	ARTICLE	IF	CITATIONS
1	High efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. <i>Oncotarget</i> , 2016, 7, 33046-33054.	1.8	93
2	Effective molecular targeting of CDK4/6 and IGF-1R in a rare <i>FUS-ERG</i> fusion <i>CDKN2A</i> -deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2016, 7, 47556-47564.	1.8	91
3	Tumor-targeting <i>Salmonella typhimurium</i> A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , 2016, 7, 85929-85936.	1.8	77
4	Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2017, 8, 35630-35638.	1.8	77
5	Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2016, 7, 71737-71743.	1.8	72
6	Risk Factors of Recurrent Lumbar Disk Herniation. <i>Journal of Spinal Disorders and Techniques</i> , 2015, 28, E265-E269.	1.9	70
7	Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2017, 8, 85516-85525.	1.8	67
8	Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. <i>Cancer Letters</i> , 2018, 432, 251-259.	7.2	59
9	Tumor-targeting <i>Salmonella typhimurium</i> A1-R combined with recombinant methioninase and cisplatin eradicates an osteosarcoma cisplatin-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic. <i>Cell Cycle</i> , 2018, 17, 801-809.	2.6	57
10	Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. <i>Cancer Letters</i> , 2018, 417, 168-173.	7.2	56
11	Tumor-Targeting <i>Salmonella typhimurium</i> A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2314-2319.	2.6	53
12	Therapeutic Targets for Bone and Soft-Tissue Sarcomas. <i>International Journal of Molecular Sciences</i> , 2019, 20, 170.	4.1	52
13	Tumor-targeting <i>Salmonella typhimurium</i> A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. <i>Oncotarget</i> , 2017, 8, 8035-8042.	1.8	50
14	Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model. <i>Anticancer Research</i> , 2018, 38, 5639-5644.	1.1	50
15	Intra-arterial administration of tumor-targeting <i>Salmonella typhimurium</i> A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Cell Cycle</i> , 2017, 16, 1164-1170.	2.6	49
16	Joint-preservation surgery for pediatric osteosarcoma of the knee joint. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 709-722.	5.9	49
17	A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatin-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. <i>Oncotarget</i> , 2017, 8, 62111-62119.	1.8	48
18	Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. <i>Oncotarget</i> , 2018, 9, 915-923.	1.8	42

#	ARTICLE	IF	CITATIONS
19	Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model. <i>Cell Cycle</i> , 2017, 16, 91-94.	2.6	41
20	Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. <i>Cell Cycle</i> , 2018, 17, 356-361.	2.6	40
21	The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. <i>Cell Cycle</i> , 2017, 16, 1046-1052.	2.6	38
22	The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy. <i>Oncotarget</i> , 2017, 8, 103129-103136.	1.8	38
23	<i>Salmonella typhimurium</i> A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. <i>Cell Cycle</i> , 2017, 16, 1288-1294.	2.6	37
24	MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). <i>Oncotarget</i> , 2017, 8, 47490-47496.	1.8	37
25	Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review. <i>Cells</i> , 2019, 8, 410.	4.1	35
26	Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Oncotarget</i> , 2018, 9, 11119-11125.	1.8	35
27	High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2739-2743.	2.6	34
28	Labeling the Stroma of a Patient-Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft-Tissue Sarcoma With Red Fluorescent Protein for Rapid Non-Invasive Imaging for Drug Screening. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 361-365.	2.6	34
29	Trabectedin and irinotecan combination regresses a cisplatin-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2019, 513, 326-331.	2.1	34
30	Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2017, 8, 75874-75880.	1.8	33
31	Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. <i>Cell Cycle</i> , 2017, 16, 1063-1069.	2.6	30
32	Growth of doxorubicin-resistant undifferentiated spindle cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 3537-3544.	2.6	30
33	Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatin, Overcome Cisplatin-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma. <i>Anticancer Research</i> , 2019, 39, 4653-4657.	1.1	30
34	Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma. <i>Cancers</i> , 2020, 12, 1758.	3.7	30
35	Pedicle versus free frozen autograft for reconstruction in malignant bone and soft tissue tumors of the lower extremities. <i>Journal of Orthopaedic Science</i> , 2014, 19, 156-163.	1.1	29
36	Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 912-917.	2.1	29

#	ARTICLE	IF	CITATIONS
37	Tumor-targeting <i>Salmonella typhimurium</i> A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. <i>Biochemical and Biophysical Research Communications</i> , 2018, 497, 1055-1061.	2.1	28
38	Pioglitazone, an agonist of PPAR $\beta$ , reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109356.	5.6	28
39	Glycogen synthase kinase 3 $\beta$ as a potential therapeutic target in synovial sarcoma and fibrosarcoma. <i>Cancer Science</i> , 2020, 111, 429-440.	3.9	28
40	Combination therapy of tumor-targeting <i>Salmonella typhimurium</i> A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 3086-3092.	2.1	27
41	The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 285-291.	2.3	27
42	Prognostic Value of Histological Response to Chemotherapy in Osteosarcoma Patients Receiving Tumor-Bearing Frozen Autograft. <i>PLoS ONE</i> , 2013, 8, e71362.	2.5	27
43	Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model. <i>Anticancer Research</i> , 2019, 39, 4079-4084.	1.1	24
44	PPAR $\beta$ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 35-40.	2.0	24
45	A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatin and doxorubicin in a patient-derived orthotopic xenograft (PDOX). <i>Oncotarget</i> , 2017, 8, 63353-63359.	1.8	24
46	Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer. <i>Cell Cycle</i> , 2018, 17, 868-873.	2.6	23
47	Efficacy of glycogen synthase kinase-3 $\beta$ targeting against osteosarcoma via activation of $\beta$ -catenin. <i>Oncotarget</i> , 2016, 7, 77038-77051.	1.8	23
48	Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model. <i>Anticancer Research</i> , 2019, 39, 4781-4786.	1.1	22
49	Temozolomide combined with irinotecan regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. <i>Oncotarget</i> , 2018, 9, 7774-7781.	1.8	22
50	Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2018, 9, 19263-19272.	1.8	22
51	Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) is Sensitive to Cisplatin and Resistant to Nab-paclitaxel. <i>Anticancer Research</i> , 2017, 37, 61-66.	1.1	20
52	MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. <i>Tissue and Cell</i> , 2018, 52, 124-128.	2.2	19
53	A combination of irinotecan/cisplatin and irinotecan/temozolomide or tumor-targeting <i>Salmonella typhimurium</i> A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2018, 505, 733-739.	2.1	18
54	Tumor targeting <i>Salmonella typhimurium</i> A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models. <i>Cell Cycle</i> , 2018, 17, 2019-2026.	2.6	18

#	ARTICLE	IF	CITATIONS
55	Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2018, 53, 30-36.	2.2	18
56	The Combination of Olaratumab with Doxorubicin and Cisplatin Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model. <i>Translational Oncology</i> , 2019, 12, 1257-1263.	3.7	18
57	Patient-derived orthotopic xenograft models of sarcoma. <i>Cancer Letters</i> , 2020, 469, 332-339.	7.2	17
58	Eribulin Suppressed Cisplatin- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Anticancer Research</i> , 2019, 39, 4775-4779.	1.1	16
59	TNF- $\alpha$ and Tumor Lysate Promote the Maturation of Dendritic Cells for Immunotherapy for Advanced Malignant Bone and Soft Tissue Tumors. <i>PLoS ONE</i> , 2012, 7, e52926.	2.5	16
60	Effective Metabolic Targeting of Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models with Recombinant Methioninase. <i>Anticancer Research</i> , 2017, 37, 4807-4812.	1.1	16
61	Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blind crossover study. <i>Cancer Medicine</i> , 2015, 4, 333-341.	2.8	15
62	Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 135-139.	2.1	15
63	Prognostic Value of Radiological Response to Chemotherapy in Patients with Osteosarcoma. <i>PLoS ONE</i> , 2013, 8, e70015.	2.5	15
64	Analysis of Stroma Labeling During Multiple Passage of a Sarcoma Imageable Patient-Derived Orthotopic Xenograft (iPDOX) in Red Fluorescent Protein Transgenic Nude Mice. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3367-3371.	2.6	14
65	Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision oncology nude-mouse model matching the patient with effective therapy. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 6598-6603.	2.6	14
66	Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>BMC Cancer</i> , 2018, 18, 840.	2.6	14
67	Tumor-targeting <i>Salmonella typhimurium</i> A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1683-1690.	1.7	14
68	A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma. <i>Pharmacological Research</i> , 2019, 142, 169-175.	7.1	14
69	A novel combined radiological method for evaluation of the response to chemotherapy for primary bone sarcoma. <i>Journal of Surgical Oncology</i> , 2012, 106, 273-279.	1.7	13
70	Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. <i>Cell Cycle</i> , 2018, 17, 627-633.	2.6	13
71	Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 967-972.	2.6	13
72	The outcomes of reconstruction using frozen autograft combined with iodine-coated implants for malignant bone tumors: compared with non-coated implants. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 735-740.	1.3	12

#	ARTICLE	IF	CITATIONS
73	Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of Cancer. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 113-120.	2.0	12
74	High-efficacy targeting of colon-cancer liver metastasis with <i>Salmonella typhimurium</i> A1-R via intra-portal-vein injection in orthotopic nude-mouse models. <i>Oncotarget</i> , 2017, 8, 19065-19073.	1.8	11
75	The usefulness of wide excision assisted by a computer navigation system and reconstruction using a frozen bone autograft for malignant acetabular bone tumors: a report of two cases. <i>BMC Cancer</i> , 2018, 18, 1036.	2.6	11
76	Tumor-targeting <i>Salmonella typhimurium</i> A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. <i>Heliyon</i> , 2018, 4, e00643.	3.2	11
77	Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Journal of Drug Targeting</i> , 2019, 27, 211-216.	4.4	11
78	Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. <i>Cancer Letters</i> , 2019, 451, 122-127.	7.2	11
79	Effectiveness of Two Novel Anionic and Cationic Platinum Complexes in the Treatment of Osteosarcoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015, 15, 390-399.	1.7	11
80	Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice. <i>Translational Oncology</i> , 2019, 12, 640-645.	3.7	10
81	The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 835-840.	5.6	10
82	The process of bone regeneration from devitalization to revitalization after pedicle freezing with immunohistochemical and histological examination in rabbits. <i>Cryobiology</i> , 2020, 92, 130-137.	0.7	10
83	Clinical course of grafted cartilage in osteoarticular frozen autografts for reconstruction after resection of malignant bone and soft-tissue tumor involving an epiphysis. <i>Journal of Bone Oncology</i> , 2020, 24, 100310.	2.4	10
84	Antimetastatic Efficacy of the Combination of Caffeine and Valproic Acid on an Orthotopic Human Osteosarcoma Cell Line Model in Nude Mice. <i>Anticancer Research</i> , 2017, 37, 1005-1012.	1.1	10
85	Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Cell Cycle</i> , 2018, 17, 722-727.	2.6	9
86	Secondary Osteoarthritis After Curettage and Calcium Phosphate Cementing for Giant-Cell Tumor of Bone Around the Knee Joint. <i>JBJS Open Access</i> , 2020, 5, e19.00068-e19.00068.	1.5	9
87	Risk Factors for Postoperative Deep Infection After Malignant Bone Tumor Surgery of the Extremities. <i>Anticancer Research</i> , 2020, 40, 3551-3557.	1.1	8
88	Clinical outcomes of frozen autograft reconstruction for the treatment of primary bone sarcoma in adolescents and young adults. <i>Scientific Reports</i> , 2021, 11, 17291.	3.3	8
89	The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1075-1082.	2.3	7
90	A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 217-223.	2.0	7



#	ARTICLE	IF	CITATIONS
91	Exquisite Tumor Targeting by Salmonella A1-R in Combination with Caffeine and Valproic Acid Regresses an Adult Pleomorphic Rhabdomyosarcoma Patient-Derived Orthotopic Xenograft Mouse Model. <i>Translational Oncology</i> , 2020, 13, 393-400.	3.7	7
92	Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models. <i>Anticancer Research</i> , 2016, 36, 4477-4482.	1.1	7
93	Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 7827-7833.	2.6	6
94	High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer. <i>Methods in Molecular Biology</i> , 2019, 1866, 149-161.	0.9	6
95	Accuracy of histological grades from intraoperative frozen-section diagnoses of soft-tissue tumors. <i>International Journal of Clinical Oncology</i> , 2020, 25, 2158-2165.	2.2	6
96	The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma. <i>Scientific Reports</i> , 2021, 11, 1989.	3.3	6
97	Calcium Phosphate Cement in the Surgical Management of Benign Bone Tumors. <i>Anticancer Research</i> , 2018, 38, 3031-3035.	1.1	6
98	Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical Trial. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	3.0	5
99	Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting <i>S. typhimurium</i> A1-R is superior to first-line chemotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 12.	17.1	5
100	Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines. <i>Anticancer Research</i> , 2017, 37, 4081-4084.	1.1	5
101	Real-time In Vivo Confocal Fluorescence Imaging of Prostate Cancer Bone Marrow Micrometastasis Development at the Cellular Level in Nude Mice. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2533-2537.	2.6	4
102	Determining Patient Satisfaction and Treatment Desires in Patients With Musculoskeletal Sarcoma of the Knee After Joint-preservation Surgery Using a Questionnaire Survey. <i>Anticancer Research</i> , 2019, 39, 1965-1969.	1.1	4
103	Recombinant Methioninase Combined With Tumor-targeting <i>Salmonella typhimurium</i> A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated Liposarcoma. <i>Anticancer Research</i> , 2020, 40, 2515-2523.	1.1	4
104	Reconstruction using a frozen autograft for a skull and humeral lesion of synchronous multicentric osteosarcoma after undergoing successful neoadjuvant chemotherapy: a case report and review of the literature. <i>BMC Surgery</i> , 2021, 21, 56.	1.3	4
105	Cystic extraskeletal osteosarcoma: Three case reports and review of the literature. <i>Molecular and Clinical Oncology</i> , 2020, 12, 468-474.	1.0	4
106	Late Recurrence of Osteosarcoma: A Report of Two Cases. <i>Journal of Orthopaedic Surgery</i> , 2014, 22, 415-419.	1.0	3
107	Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2019, 58, 107-111.	2.2	3
108	Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 351-358.	2.0	3

#	ARTICLE	IF	CITATIONS
109	Distal Tibial Tuberosity Focal Dome Osteotomy Combined With Intra-Articular Condylar Osteotomy (Focal Dome Condylar Osteotomy) for Medial Osteoarthritis of the Knee Joint. <i>Arthroscopy Techniques</i> , 2020, 9, e1079-e1086.	1.3	3
110	Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors. <i>Anticancer Research</i> , 2018, 38, 4065-4072.	1.1	2
111	Methioninase Cell-Cycle Trap Cancer Chemotherapy. <i>Methods in Molecular Biology</i> , 2019, 1866, 133-148.	0.9	2
112	Long-term survival in a patient with Hutchinson-Gilford progeria syndrome and osteosarcoma: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 854-863.	0.8	0
113	Precision medicine for recalcitrant cancers with the patient-derived orthotopic xenograft (PDOX) mouse models for identification of effective therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23164-e23164.	1.6	0
114	Primary total knee arthroplasty assisted by computed tomography-free navigation for secondary knee osteoarthritis following massive calcium phosphate cement packing for distal femoral giant-cell bone tumor treatment: a case report. <i>BMC Musculoskeletal Disorders</i> , 2022, 23, 170.	1.9	0